Rajesh Krishna, Anneliene H. Jonker, Thomas Morel, Ken Sakushima, Anna M. G. Pasmooij, Daniel O’Connor
{"title":"IRDiRC 关于在罕见病治疗开发中应用数字生物标记的观点","authors":"Rajesh Krishna, Anneliene H. Jonker, Thomas Morel, Ken Sakushima, Anna M. G. Pasmooij, Daniel O’Connor","doi":"10.1038/d41573-024-00196-z","DOIUrl":null,"url":null,"abstract":"New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"46 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases\",\"authors\":\"Rajesh Krishna, Anneliene H. Jonker, Thomas Morel, Ken Sakushima, Anna M. G. Pasmooij, Daniel O’Connor\",\"doi\":\"10.1038/d41573-024-00196-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.\",\"PeriodicalId\":18847,\"journal\":{\"name\":\"Nature Reviews Drug Discovery\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/d41573-024-00196-z\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/d41573-024-00196-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases
New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
